62 related articles for article (PubMed ID: 29093296)
1. Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.
St Onge CM; Pagare PP; Zheng Y; Arriaga M; Stevens DL; Mendez RE; Poklis JL; Halquist MS; Selley DE; Dewey WL; Banks ML; Zhang Y
J Med Chem; 2024 Jun; 67(11):9552-9574. PubMed ID: 38814086
[TBL] [Abstract][Full Text] [Related]
2. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
3. Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.
Beck TC; Reichel CM; Helke KL; Bhadsavle SS; Dix TA
Eur J Pharmacol; 2019 Aug; 856():172396. PubMed ID: 31103632
[TBL] [Abstract][Full Text] [Related]
4. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an Ortho-Substituted
Li Z; Ye R; He Q; Lu J; Sun Y; Sun X; Tang S; Hu S; Chai J; Kong L; Liu X; Chen J; Fang Y; Lan Y; Xie Q; Liu J; Shao L; Fu W; Wang Y; Li W
J Med Chem; 2024 May; 67(9):7112-7129. PubMed ID: 38647397
[TBL] [Abstract][Full Text] [Related]
6. Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.
Uprety R; Che T; Zaidi SA; Grinnell SG; Varga BR; Faouzi A; Slocum ST; Allaoa A; Varadi A; Nelson M; Bernhard SM; Kulko E; Le Rouzic V; Eans SO; Simons CA; Hunkele A; Subrath J; Pan YX; Javitch JA; McLaughlin JP; Roth BL; Pasternak GW; Katritch V; Majumdar S
Elife; 2021 Feb; 10():. PubMed ID: 33555255
[TBL] [Abstract][Full Text] [Related]
7. The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.
Mysels D; Sullivan MA
Am J Addict; 2009; 18(4):272-6. PubMed ID: 19444730
[TBL] [Abstract][Full Text] [Related]
8. Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain.
Muratspahić E; Tomašević N; Koehbach J; Duerrauer L; Hadžić S; Castro J; Schober G; Sideromenos S; Clark RJ; Brierley SM; Craik DJ; Gruber CW
J Med Chem; 2021 Jul; 64(13):9042-9055. PubMed ID: 34162205
[TBL] [Abstract][Full Text] [Related]
9. Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology.
Kajino K; Tokuda A; Saitoh T
J Biochem; 2024 Mar; 175(4):337-355. PubMed ID: 38382631
[TBL] [Abstract][Full Text] [Related]
10. Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders.
Li P; Zhang Q; Zheng H; Qiao Y; Snyder GL; Martin T; Yao W; Zhang L; Davis RE
J Med Chem; 2024 Jun; 67(11):9355-9373. PubMed ID: 38805667
[TBL] [Abstract][Full Text] [Related]
11. Molecular design, construction and analgesic mechanism insights into the novel transdermal fusion peptide ANTP-BgNPB.
Peng X; Tao H; Xia F; Zhu M; Yang M; Liu K; Hou B; Li X; Li S; He Y; Huan W; Gao F
Bioorg Chem; 2024 Jul; 148():107482. PubMed ID: 38795582
[TBL] [Abstract][Full Text] [Related]
12. Structure-based drug discovery facilitates future painkiller development.
Li Y; Li T; Du Y; Wu S
Clin Transl Med; 2022 Nov; 12(11):e1120. PubMed ID: 36412509
[No Abstract] [Full Text] [Related]
13. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
Che T; Majumdar S; Zaidi SA; Ondachi P; McCorvy JD; Wang S; Mosier PD; Uprety R; Vardy E; Krumm BE; Han GW; Lee MY; Pardon E; Steyaert J; Huang XP; Strachan RT; Tribo AR; Pasternak GW; Carroll FI; Stevens RC; Cherezov V; Katritch V; Wacker D; Roth BL
Cell; 2018 Jan; 172(1-2):55-67.e15. PubMed ID: 29307491
[TBL] [Abstract][Full Text] [Related]
14. A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists.
Mores KL; Cummins BR; Cassell RJ; van Rijn RM
Front Pharmacol; 2019; 10():407. PubMed ID: 31057409
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications.
Ji MJ; Yang J; Gao ZQ; Zhang L; Liu C
Front Neurosci; 2021; 15():642493. PubMed ID: 33716658
[TBL] [Abstract][Full Text] [Related]
16. Strategies for Developing
Paton KF; Atigari DV; Kaska S; Prisinzano T; Kivell BM
J Pharmacol Exp Ther; 2020 Nov; 375(2):332-348. PubMed ID: 32913006
[TBL] [Abstract][Full Text] [Related]
17. AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression.
Xiang HC; Lin LX; Hu XF; Zhu H; Li HP; Zhang RY; Hu L; Liu WT; Zhao YL; Shu Y; Pan HL; Li M
J Neuroinflammation; 2019 Feb; 16(1):34. PubMed ID: 30755236
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
